Immunodeficiency Diseases
Dupilumab safe, effective for atopic dermatitis in youth with inborn errors of immunity
Dupilumab was safe and effective in treating a group of six children and young adults with inborn errors of immunity and moderate to severe atopic dermatitis, according to a study published in Pediatric Allergy and Immunology.
Challenges remain in genetic testing for primary immunodeficiencies
WASHINGTON — Genetic testing has increased the number of patients diagnosed with primary immunodeficiencies, Eveline Wu, MD, MSCR, told Healio during the American Academy of Allergy, Asthma & Immunology Annual Meeting.
FDA approves Hizentra 50 mL prefilled syringes for primary immunodeficiency treatment
The FDA has approved 50 ml/10 gm prefilled syringes of Hizentra for treating patients with primary immunodeficiency aged 2 years and older and adults with chronic inflammatory demyelinating polyneuropathy, according to a press release.
Q&A: Expanded rollout of adenosine deaminase deficiency newborn screenings recommended
Tandem mass spectroscopy screenings for newborns can identify partial or delayed adenosine deaminase deficiencies, which can have potentially fatal complications, according to a review published in Annals of Allergy, Asthma & Immunology.
Newborn screening strategy identifies otherwise missed adenosine deaminase deficiencies
Including tandem mass spectroscopy in newborn screenings to identify adenosine deaminase deficiencies could save lives while adding negligible costs, according to a study published in Annals of Allergy, Asthma & Immunology.
FDA approves cutaquig for children with primary humoral immunodeficiency
The FDA approved immune globulin subcutaneous (human)-hipp, 16.5% solution, or cutaquig, for the treatment of children aged at least 2 years with primary humoral immunodeficiency, according to a press release.